All files are available from the NHIS-NSC 2002-2013 database.

Introduction {#sec001}
============

Bone is one of the most common sites of metastasis from advanced solid cancers, and bone metastases occur in 65--80% of patients with advanced prostate or breast cancer, 40--50% patients with lung cancer, and in \<10% of those with gastrointestinal cancer \[[@pone.0234927.ref001]--[@pone.0234927.ref003]\]. The bone is a dynamic organ that undergoes constant remodeling with simultaneous bone formation and resorption by osteoblasts and osteoclasts, respectively. In a normal healthy bone, the interaction between osteoblasts and osteoclasts is well balanced. However, once cancer cells invade the bone tissue, bone remodeling balance is disrupted, leading to destruction of the skeleton \[[@pone.0234927.ref004]\]. In addition, cancer cells that have metastasized to the bone secrete cytokines and growth factors causing a change in the microenvironment. Bone can also serve as a reservoir for dormant cancer cells from other organs, which can lead to full-blown metastases after a long period of dormancy \[[@pone.0234927.ref003]\].

Bone metastasis is a leading cause of pain in cancer patients. Bone pain due to metastasis is mainly caused by destruction of the bone structure, leading to periosteal irritation and nerve damage \[[@pone.0234927.ref005]\]. Moreover, it increases the risk of complications referred to as skeletal-related events (SREs), including pathologic fracture, spinal cord compression, palliative radiation to the bone, and palliative bone surgery \[[@pone.0234927.ref006]\]. Bone metastases and SREs greatly affect the quality of life of patients, in addition to increasing the medical costs \[[@pone.0234927.ref007]\], and mortality risk \[[@pone.0234927.ref001], [@pone.0234927.ref008]\].

Various studies have reported the development of bone metastases from breast, prostate, and lung cancers. However, with an increasing number of cancer survivors, bone metastasis has become a critical issue, and the incidence of bone metastasis in other type of cancer should be investigated as well. Moreover, there exists a cross-country variation in the pattern and occurrence of bone metastasis from each type of primary cancer. There are a limited number of population-based real-world studies reporting on the occurrence of bone metastasis in patients with solid cancers \[[@pone.0234927.ref009]--[@pone.0234927.ref011]\]. This study aimed to investigate the occurrence and pattern of bone metastases and SREs in selected patients with solid cancers using the Korean nationwide health insurance cohort database.

Materials and methods {#sec002}
=====================

Data source {#sec003}
-----------

The Korean National Health Insurance Service (KNHIS) enrolls more than 97% of the entire Korean population. The KNHIS established a national sample cohort, the National Health Insurance Service-National Sample Cohort (NHIS-NSC), for research purposes that was randomly selected and comprised 2.2% of the total eligible population \[[@pone.0234927.ref012]\]. We used the NHIS-NSC claims data from 2002 to 2012. This database provides detailed information on demographics and healthcare utilization, including diagnostic codes (International Classification of Diseases 10^th^ revision, ICD-10), procedure codes, and prescriptions.

Study population {#sec004}
----------------

We identified all newly diagnosed patients with primary stomach, colorectal, liver, lung, breast, prostate, and other genitourinary (GU) cancers, which were considered as major types of cancers in Korea \[[@pone.0234927.ref013]\] from January 2003 to December 2010 (ICD-10 codes: C16, C18--20, C22, C34, C50, C61, C51--57, and C60--68). We used a 1-year washout period to exclude cancer patients who had been diagnosed in the past. Other GU cancers included malignant neoplasms of the female genital organs, male genital organs, and the urinary tract. We excluded participants who were aged less than 20 years and those with multiple primary cancers. Patients were followed up for at least 2 years to assess for the development of bone metastases and SREs. Patients diagnosed with bone metastases were identified using a diagnostic code (ICD-10 code for bone metastasis: C795). SREs were identified using the diagnostic codes for pathologic fracture (ICD-10 code: S22, S32, S42.2--42.4, S52, S62, S72, S82.1--82.4, T08, T12, and M80.0) and spinal cord compression (ICD-10 code: G95.2, G55.0, and G55.8), and the procedure codes for bone radiation (HD051--HD061, HD080--HD089, HD110--HD112, HD211, HD212, HD121, and HZ271) and bone surgery (N0304-N0309, N0451-N0453, N0466-N0469, N0471-N0475, N0590, N0601-N0617, N0630, N0641-N0645, N0981-N0986, N0991-N0995, N1466, N1469, N1497-N1499, N2461-N2470, N2491-N2499, S4694-S4696, S4704-S4709, S6691-S6696).

Statistical analysis {#sec005}
--------------------

Data on the occurrence of bone metastasis in each type of cancer and basic demographic characteristics of the patients were obtained. The median overall survival was calculated from the date of primary cancer diagnosis to the date of death. We also calculated the median survival after bone metastasis, which was defined as the period from the diagnosis of bone metastasis to death. Time-to-event analysis was performed to estimate the time interval from the development of bone metastasis to the occurrence of SREs, or to estimate the cumulative incidence of SREs due to bone metastasis. Survival analysis was performed using the Kaplan--Meier method. All analyses were performed using SAS version 9.4 (SAS Institute Inc., Cary, NC, USA).

Statement of ethics {#sec006}
-------------------

This study was approved by the Institutional Review Board of the National Health Insurance Service Ilsan Hospital (NHIMC 2016-03-007), and the requirement for written informed consent was waived.

Results {#sec007}
=======

We identified 21,562 patients with one of the seven types of cancers diagnosed between 2003 and 2010 who were followed up until the end of 2012 ([Table 1](#pone.0234927.t001){ref-type="table"}). Among them, 1,849 patients had been newly diagnosed with bone metastases at or after the diagnosis of the primary cancer, accounting for 8.6% of the entire cohort. Bone metastases were commonly observed in breast cancer (18.8%), prostate cancer (17.5%), and lung cancer (13.7%) patients

10.1371/journal.pone.0234927.t001

###### Selection of patients with cancer and bone metastasis.

![](pone.0234927.t001){#pone.0234927.t001g}

                                                                 Criteria     Stomach      Colorectal   Liver         Lung          Breast        Prostate     Other GU
  -------------------------------------------------------------- ------------ ------------ ------------ ------------- ------------- ------------- ------------ --------------
  Step 1 NHIS-NSC 2002--2012 cancer diagnosis (n)                8,754        7,468        5,527        6,383         4,380         2,411         6,385        41,308
  Step 2 No evidence of any other primary cancer (n)             7,706        6,353        4,793        5,555         4,063         1,940         5,590        36,000
  Step 3 New diagnosis from 2003to 2010 and age \>20 years (n)   4,653        3,860        3,024        3,489         2,221         1,109         3,206        21,562
  Step 4 New diagnosis of bone metastasis (n, %)                 190 (4.1%)   169 (4.4%)   173 (5.7%)   479 (13.7%)   417 (18.8%)   194 (17.5%)   227 (7.1%)   1,849 (8.6%)

GU, genitourinary; NHIS-NSC, National Health Insurance Service-National Sample Cohort

[Table 2](#pone.0234927.t002){ref-type="table"} shows the characteristics of patients with bone metastasis according to the primary cancer type. For the majority of the cancers, except other GU cancers, bone metastases were more common in men than in women. Among patients with stomach, colorectal, and lung cancer, bone metastases frequently occurred in patients who were in their sixties. In prostate cancer, the incidence of bone metastases increased with age, whereas in breast cancer, it decreased with age. Bone metastases showed an increasing trend in rural areas compared to that in urban areas. Household income had no impact on the occurrence of bone metastasis. The diagnosis of bone metastasis was made together with the initial cancer diagnosis in 46.3% of the patients. The incidence of bone metastasis was the highest in lung cancer patients (64.3%), followed by those with breast cancer (47.7%) and prostate cancer (47.4%). For metachronous bone metastasis, the average time between primary cancer diagnosis and bone metastasis was 18.9 months (standard deviation: 21.6 months). The shortest interval between the diagnoses of primary cancer and bone metastasis was seen in lung cancer patients at 9 months, followed by breast cancer patients at 14.9 months, and prostate cancer patients at 17.4 months

10.1371/journal.pone.0234927.t002

###### Characteristics of patients with bone metastasis according to the primary cancer type.

![](pone.0234927.t002){#pone.0234927.t002g}

  Characteristics (no., %)   Stomach                                      Colorectal    Liver         Lung          Breast        Prostate      Other GU      Total         p-value       
  -------------------------- -------------------------------------------- ------------- ------------- ------------- ------------- ------------- ------------- ------------- ------------- --------
  Sex                                                                                                                                                                                     
                             Male                                         116 (61.1%)   91 (53.8%)    128 (74.0%)   354 (73.9%)   1 (0.2%)      194 (100%)    97 (42.7%)    981           \<0.01
                             Female                                       74 (38.9%)    78 (46.2%)    45 (26.0%)    125 (26.1%)   416 (99.8%)   0             130 (57.3%)   868           
  Age group (years)                                                                                                                                                                       
                             20--49                                       45 (23.7%)    32 (18.9%)    43 (24.9%)    47 (9.8%)     223 (53.5%)   6 (3.1%)      57 (25.1%)    453           \<0.01
                             50--59                                       45 (23.7%)    34 (20.1%)    56 (32.4%)    100 (20.9%)   124 (29.7%)   21 (10.8%)    57 (25.1%)    437           
                             60--69                                       58 (30.5%)    56 (33.1%)    41 (23.7%)    176 (36.7%)   48 (11.5%)    73 (37.6%)    64 (28.2%)    516           
                             ≥70                                          42 (22.1%)    47 (27.8%)    33 (19.1%)    156 (32.6%)   22 (5.3%)     94 (48.5%)    49 (21.6%)    443           
  Region                                                                                                                                                                                  
                             Urban                                        79 (41.6%)    75 (44.4%)    64 (37.0%)    202 (42.2%)   223 (53.5%)   87 (44.8%)    106 (46.7%)   836           \<0.01
                             Rural                                        111 (58.4%)   94 (55.6%)    109 (63.0%)   277 (57.8%)   194 (46.5%)   107 (55.2%)   121 (53.3%)   1,013         
  Income                                                                                                                                                                                  
                             1%--40%                                      62 (32.6%)    53 (31.4%)    46 (26.6%)    149 (31.1%)   116 (27.8%)   49 (25.3%)    62 (27.3%)    537           0.18
                             41%--80%                                     70 (36.8%)    62 (36.7%)    65 (37.6%)    189 (39.5%)   177 (42.4%)   64 (33.0%)    95 (41.9%)    722           
                             80%--100%                                    58 (30.5%)    54 (32.0%)    62 (35.8%)    141 (29.4%)   124 (29.7%)   81 (41.8%)    70 (30.8%)    590           
  Bone metastasis                                                                                                                                                                         
                             At the initial cancer diagnosis              59 (33.1%)    43 (25.4%)    79 (45.7%)    308 (64.3%)   199 (47.7%)   92 (47.4%)    77 (33.9%)    857 (46.3%)   
                             Time to bone metastasis (Mean, SD) (month)   23.4 (22.6)   28.9 (25.5)   16.3 (21.2)   9.0 (15.2)    14.9 (20.6)   17.4 (22.0)   22.6 (23.8)                 

GU, genitourinary; SD, standard deviation

Among the 1,849 patients with bone metastases, 833 (45.1%) experienced SREs ([Table 3](#pone.0234927.t003){ref-type="table"}). SREs most commonly occurred in patients with lung cancer (53.4%), followed by those with liver cancer (50.9%), prostate cancer (45.9%), breast cancer (43.6%), and colorectal cancer (40.2%). The most common SRE was radiation therapy to the bone, which was administered to 31.7% of patients who developed bone metastasis and to 70.5% of patients with SREs. Patients with lung cancer (44.9%) and liver cancer (37.6%) more frequently received radiation therapy for bone metastasis. Fractures occurred in 10.9% of all patients with bone metastases and were the most frequent in prostate cancer (18.0%). A total of 8.3% patients underwent bone surgery and 3.4% experienced spinal cord compression. [Fig 1](#pone.0234927.g001){ref-type="fig"}. shows the total number of SREs according to the cancer type. The majority of SREs occurred within 1 month of bone metastasis, except in breast (5.9 months) and prostate (4.7 months) cancers. SREs were significantly more frequent in breast cancer patients when the bone metastasis was diagnosed simultaneously with the primary cancer (p \< 0.001). We estimated the cumulative incidence of SREs ([Fig 2](#pone.0234927.g002){ref-type="fig"}). The estimated cumulative incidence of SREs is summarized in [S1 Table](#pone.0234927.s001){ref-type="supplementary-material"}.

![Number of skeletal-related events.](pone.0234927.g001){#pone.0234927.g001}

![Cumulative risk of skeletal-related events (%).](pone.0234927.g002){#pone.0234927.g002}
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###### Overall occurrence of skeletal-related events (number of patients).

![](pone.0234927.t003){#pone.0234927.t003g}

  Characteristics (No., %)               Stomach      Colorectal   Liver        Lung          Breast        Prostate     Other GU     Total
  -------------------------------------- ------------ ------------ ------------ ------------- ------------- ------------ ------------ -------------
  Total patients with SREs               72 (37.9%)   68 (40.2%)   88 (50.9%)   256 (53.4%)   182 (43.6%)   89 (45.9%)   78 (34.4%)   833 (45.1%)
  Fracture                               27 (14.2%)   20 (11.8%)   13 (7.5%)    33 (6.9%)     50 (12.0%)    35 (18.0%)   23 (10.1%)   201 (10.9%)
  Cord compression                       11 (5.8%)    11 (6.5%)    6 (3.5%)     11 (2.3%)     8 (1.9%)      6 (3.1%)     10 (4.4%)    63 (3.4%)
  Radiation                              34 (17.9%)   31 (18.3%)   65 (37.6%)   215 (44.9%)   142 (34.1%)   55 (28.4%)   45 (19.8%)   587 (31.7%)
  Surgery                                17 (8.9%)    18 (10.7%)   21 (12.1%)   46 (9.6%)     21 (5.0%)     18 (9.3%)    13 (5.7%)    154 (8.3%)
  Median time from BM to SREs (months)   0.5          0.4          0.0          0.4           5.9           4.7          0.1           

GU, genitourinary; BM, bone metastasis; SREs, skeletal-related events

The overall survival of patients varied with the primary cancer type, with OS being the shortest in lung cancer (10 months) and the longest in breast cancer (39 months). The median survival after bone metastasis was 3.5 months in stomach cancer patients, 4 months in liver cancer patients, 5 months in lung and colorectal cancer patients, 9 months in other GU cancer patients, 16 months in prostate cancer patients, and 19 months in breast cancer patients ([Fig 3](#pone.0234927.g003){ref-type="fig"}). [Fig 4](#pone.0234927.g004){ref-type="fig"} and [Fig 5](#pone.0234927.g005){ref-type="fig"} present Kaplan-Meier overall survival curve for whole cancer patients and survival after bone metastasis, respectively.

![Overall survival and survival after the diagnosis of bone metastasis.](pone.0234927.g003){#pone.0234927.g003}

![Kaplan-Meier survival curve for overall survival.](pone.0234927.g004){#pone.0234927.g004}

![Kaplan-Meier survival curve for overall survival after bone metastasis.](pone.0234927.g005){#pone.0234927.g005}

Discussion {#sec008}
==========

Our study included 1,849 patients with bone metastases arising from seven major types of cancer who were enrolled from the Korean National Sample Cohort database. We found that 8.6% of the newly diagnosed cancer patients had bone metastases. The overall occurrence of bone metastasis from solid cancers was similar to that reported from other countries. In 2004, Schulman et al. reported that 5.3% of cancer patients in the United States (US) had metastatic bone disease \[[@pone.0234927.ref007]\]. A recent US study identified patients with solid cancer from 2004 to 2013 and reported that 6.9% of the entire study population had bone metastases at diagnosis and during follow-up \[[@pone.0234927.ref011]\]. A Danish population-based cohort study registered patients diagnosed with cancer between 1994 and 2010 and showed that 7.5% of patients with prostate, breast, and lung cancer, which were the three most common primary cancers out of 10 cancer types, had metastatic bone disease \[[@pone.0234927.ref010]\]. Similarly, a retrospective cohort study conducted in Thailand from 2006 to 2015 demonstrated that 7.7% of the patients diagnosed with the 10 most common cancer types had bone metastases \[[@pone.0234927.ref009]\]. The incidence of bone metastasis according to the cancer type differed between countries. However, most previous studies, including our study, showed that the top three leading cancers associated with the development of bone metastasis were prostate, breast, and lung cancers \[[@pone.0234927.ref009]--[@pone.0234927.ref011]\]. In comparison, less than 5% of stomach and colorectal cancer patients developed bone metastasis, which is consistent with the historical data (3%--5%) \[[@pone.0234927.ref002]\].

We found that the mean time from primary cancer diagnosis to bone metastasis was 18.9 months, and this is consistent with the findings of a US study, which reported that the incidence of bone metastasis in patients with solid cancer mostly increased in the first 2 years \[[@pone.0234927.ref011]\]. According to our data, lung cancer patients demonstrated the shortest interval between the diagnoses of primary cancer and bone metastasis and also the highest proportion (64.3%) of concomitant diagnoses for primary tumor and bone metastasis. In a US study, 64.4% of lung cancer patients were diagnosed with bone metastases at the time of the initial cancer diagnosis \[[@pone.0234927.ref014]\]. This may be due to the rapid and aggressive metastatic process in lung cancer, which can be attributed to the lung cancer cells swiftly obtaining the ability to infiltrate and colonize other organs \[[@pone.0234927.ref015]\]. However, in other cancers, especially in colorectal cancer, there was a longer interval to overt bone metastasis (mean: 28.9 months), and the incidence of simultaneous diagnosis of the primary tumor and bone metastasis was only 25.4%. These findings suggest that there are different mechanisms underlying the development of bone metastases in different cancer types, and these mechanisms depend on the patient's oncogenic background as well as the microenvironment in each type of cancer \[[@pone.0234927.ref015]\].

Among all patients with bone metastasis, 45.1% developed SREs. With regard to lung and liver cancers, SREs occurred in more than 50% patients, whereas in breast, prostate, and colorectal cancer patients, about 40% or more developed SREs. In previous breast cancer trials, a total of 64% of patients who did not use bone-modifying agents (BMAs) experienced SREs, and 43--45% of patients who used BMA developed SREs \[[@pone.0234927.ref016], [@pone.0234927.ref017]\]. In case of prostate cancer, approximately 44--49% of patients in the placebo group developed SREs, while 33--41% of the patients in the BMA group developed SREs \[[@pone.0234927.ref018]--[@pone.0234927.ref020]\]. Regarding lung cancer and other solid cancers, previous randomized trials have revealed that 44--46% of patients in the placebo group and 35--39% of patients in the BMA group developed SREs \[[@pone.0234927.ref021], [@pone.0234927.ref022]\]. Compared with those of placebo-controlled clinical trials, our real-world data showed a higher incidence of SREs in lung cancer patients and a similar or lower incidence of SREs in breast and prostate cancer patients. In addition, compared with that in recent clinical trials on novel BMAs (such as zoledronate or denosumab), the occurrence of SREs in our routine practice was much higher. A pooled analysis of phase 3 trials showed overall SRE incidence rate of 33.5%, 38.2%, and 28.5% in patients with breast, prostate, and other solid cancers, respectively \[[@pone.0234927.ref023]\]. This difference might be because of the insurance coverage in Korea as well as the differences in clinical practice in the real world. However, there is a lack of data on stomach cancer, which has the highest incidence in Korea. A previous Italian multicenter study reported an overall SRE incidence of 31% in stomach cancer patients, and radiation therapy comprised 47.1% of the SREs \[[@pone.0234927.ref024]\]. The Memorial Sloan Kettering Cancer Center (MSKCC) evaluated 459 patients with liver cancer. Among them, 32.9% had bone metastasis, and the overall occurrence of SREs in patients with bone metastasis was 56.3% \[[@pone.0234927.ref025]\]. These findings are similar to our results in patients with stomach or liver cancer. The most common SRE was radiation therapy (31.7%), which has been frequently reported in other Korean studies \[[@pone.0234927.ref026], [@pone.0234927.ref027]\], but is less frequently reported in other countries \[[@pone.0234927.ref002], [@pone.0234927.ref028]\]. The second commonest SRE was pathologic fracture, accounting for 10.9% of the cases, and more than half of these SREs were fractures of the spine or pelvis.

The estimated 3-year cumulative incidence of SREs was 45--55% in all cancer types. The 1-year cumulative SRE incidence rates in lung cancer (47.8%), breast cancer (32.1%), and prostate cancer (29.9%) patients were relatively low compared to other countries. According to data from a US study, the SRE incidence rate in both lung cancer and breast cancer patients was 45.4%, while that in prostate cancer patients was 30.4% \[[@pone.0234927.ref014]\]. A Danish population study reported an SREs incidence rate of 55.0% in lung cancer \[[@pone.0234927.ref008]\], 46.1% in prostate cancer \[[@pone.0234927.ref029]\], and 38.5% in breast cancer \[[@pone.0234927.ref030]\]. A longitudinal view of the cumulative incidence of SREs ([Fig 2](#pone.0234927.g002){ref-type="fig"}) showed the most significant change over time in case of prostate cancer. Therefore, patients with prostate cancer should be carefully followed up for SREs because they show longer survival than those with other cancer types of cancers.

The median time from the diagnosis of bone metastasis to SREs was within 1 month, except in breast and prostate cancer. An Italian study reported that the median time from bone metastasis to the occurrence of SREs was 2 months in colorectal cancer, and the survival duration after SREs was estimated to be 4.5 months \[[@pone.0234927.ref028]\]. The MSKCC group reported that in liver cancer patients, the median time from bone metastasis to the development of SREs was 0.8 months. Meanwhile, an Italian study reported that in stomach cancer patients, the median time from bone metastasis to the development of SREs was 2 months \[[@pone.0234927.ref024], [@pone.0234927.ref025]\]. These findings are remarkably similar to our results. Our study patients only survived 3--5 months after the occurrence of SREs. Consequently, following the diagnosis of bone metastasis, physicians should closely follow-up the development of SREs and manage them in a timely manner.

We estimated the median survival after the diagnosis of bone metastasis along with the overall survival for each cancer type. The overall survival depends predominantly on the prognosis of the primary cancer; it was longer in breast and prostate cancer patients and shorter in lung cancer patients. Regarding median survival after the diagnosis of bone metastasis, it was the shortest in stomach cancer patients (3.5 months), followed by liver cancer (four months), lung cancer, and colorectal cancer (five months) patients. Generally, the majority of these cancers had a poor prognosis. However, in colorectal cancer, the prognosis was unusual. The median overall survival in colorectal cancer was 23 months, which was longer than that in other cancer, but the median survival after bone metastasis was poor. An Italian study also reported that the period from bone metastasis to death was only 7 months in colorectal cancer patients \[[@pone.0234927.ref028]\]. In contrast, in breast and prostate cancers, bone metastases developed in the middle of the disease course. Since, patients with these cancers tended to live for more than 1 year, and they had more chances of experiencing SREs \[[@pone.0234927.ref027]\]. Accordingly, a multidisciplinary team approach should be used for the management of breast and prostate cancer patients to provide supportive care for bone metastases along with potential aggressive treatment for SREs such as fractures and spinal cord compression.

This study has several limitations. Although 2% of the national sample cohort database was utilized in this study, the patients were selected based on the diagnostic code, which may be less accurate than the data from chart reviews or cross-sectional studies; therefore, the number of patients could have been underestimated. Consequently, caution is required when generalizing our data to the whole Korean population. For the definition of radiation therapy, we could not distinguish the reasons for radiation therapy because we used the claims data. Radiation therapy is usually administered when bone pain is present, but sometimes, it is also used for asymptomatic patients to reduce the risk of SREs. Lastly, we could not obtain specific cancer data such as those on cancer stage and subtype from the claims data.

However, the results of our study are significant because they show the current incidence and trends of bone metastasis and SREs in Korean patients with solid cancers and provide physicians valuable insight into this patient population. An additional strength of our study is that it presents the epidemiology and natural history of bone metastasis in stomach and liver cancer, both of which are prevalent in Asia. With the development of cancer therapy and an increase in the rates of early diagnosis, the number of long-term cancer survivors continues to rise, and maintaining the well-being of these patients is a major issue in cancer care. Therefore, physicians should consider active management of bone metastases to control related symptoms and to prevent SREs. The choice of treatment should be based on the course of the disease and performance status of the patient.

Conclusion {#sec009}
==========

In summary, this study estimated the occurrence of bone metastasis and subsequent SREs in selected Korean patients diagnosed with various types of solid cancers. We also examined the timing of bone metastasis and SREs during the course of the disease. We found that the development and timing of bone metastasis and SREs differed according to the type of primary cancer. Metastatic bone disease arising from solid cancer is incurable. Therefore, maintaining the quality of life of the patients and providing full supportive care are of utmost importance. Our data can be used as a basis for planning the management of patients with bone metastases from solid cancers.

Supporting information {#sec010}
======================

###### Cumulative risk of SREs (%).
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Click here for additional data file.
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The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

Reviewer \#3: Yes

Reviewer \#4: Yes

Reviewer \#5: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

Reviewer \#3: Yes

Reviewer \#4: Yes

Reviewer \#5: No

\*\*\*\*\*\*\*\*\*\*

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: The enclosed manuscript by Hong et al. is an analysis of bone metastases and skeletal related events in Korea using a national database. The authors find an incidence of bone metastases and SREs in an Asian population similar to what has been published from other parts of then world. The authors look at survival after bone mets and SREs and provide useful information on the natural history of bone metastases. The incidence of bone metastases in stomach and liver cancer is useful as these diseases occur frequently in this population.

I believe this article adds to the worldwide information on the scope of the problem of bone metastases.

I suggest acceptance of this manuscript with no revision needed

Reviewer \#2: This study is a good dataset may contribute to the better identification of bone health in patients with solid cancers. However, I have some concerns on the methodology.

Specific Comments

1\. Which ICD-code of bone surgery SRE in this study ?

2\. The literature showed that once a patient experiences an SRE, the risk of subsequent SRE is increase. I wonder if this study had the data on the cumulative number of SREs in each patient ?

3\. Pathologic fracture is strongly associated with an increased risk of death. How about the differences of overal survival between BM patients with fracture SRE and those without fracture SRE, and those without SRE.

4\. In the discussion part, please correct \"1,845 bone metastasis patients\" into \"1,849\".

Reviewer \#3: The definition of SRE (Skeletal-related events) about radiation is slightly different for each paper. (severe bone pain requiring radiation vs. just radiation to bone)

In some cases, radiation therapy is administered for asymptomatic bone metastases in patients to reduce the risk of skeletal-related events. Therefore, it must be noted and the authors should concern and describe about this.

Reviewer \#4: This is well written and organized paper. The authors addressed the bone metastasis and SRE in patients with diverse solid cancers in Korea.

Minor points

1\. In material and methods section. I can't easily understand the following sentences. Please explain. "We excluded paticipants who were aged less than 20 years\~ at least 2 years to assess for bone metastases and SREs" What does washout mean?

2\. Please add Kaplan-Meier survival curves for OS, and survival after bone metastasis if possible. (You can add just 2 figures, one for OS including all cancer types, and the other for survival after bone metastasis)

Reviewer \#5: This study showed the epidemiology of bone metastases and skeletal-related events (SREs) in Korea using claims data from the National Health Insurance Service National Sample Cohort. However, the study presented only numerical value. Statistic data was not connected to QOL or medical cost, although authors mentioned in discussion and conclusion. I can't discover a new and unique point from this study. Therefore, unfortunately, I think that this manuscript is not candidate for publication in PLOS ONE.

Major point

1\. This study focused on 7 major cancer types (stomach, colorectal, liver, lung, breast, prostate, and other genitourinary cancers). The reference about Korea cancer incidence should be added.

2\. Why did authors use the only C795 for bone metastases? The reason should be documented in discussion.

3\. Authors defined pathologic fracture, spinal cord compression, bone radiation, and bone surgery as SREs. Why did authors exclude hypercalcemia from SREs? And what was the procedure cord for bone surgery? How did authors handle overlapping data from the different cords? I don't understand this sentence "In addition, patients diagnosed in 2002 were excluded for washout and were followed up for at least 2 years to assess for bone metastases and SREs".

4\. In result, authors commented that bone mets increased with age and there was no difference in region or household. Statistical p value should be added. If authors did not use statistical analysis, the content should be corrected.

5\. Discussion is ambiguous and extensive. This cloud the issue. Please clarify authors' suggestion and present specified contents.

6\. The manuscript is not easy to read and the English used really should be checked for grammar and spelling.

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: Yes: Lan T. Ho-Pham

Reviewer \#3: Yes: IK JAE LEE

Reviewer \#4: Yes: Jun Eul Hwang

Reviewer \#5: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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1\. Which ICD-code of bone surgery SRE in this study?

Thank you for comment. I added procedure codes for bone surgery in study population.

2\. The literature showed that once a patient experiences an SRE, the risk of subsequent SRE is increase. I wonder if this study had the data on the cumulative number of SREs in each patient?

Thank you for your comment. I agree with your opinion, however we focused only on the first event of each SRE in this paper. We do not have information about cumulative number of SREs.

3\. Pathologic fracture is strongly associated with an increased risk of death. How about the differences of overall survival between BM patients with fracture SRE and those without fracture SRE, and those without SRE.

Thank you for your comment.

We tried to compare the overall survival according to each SRE, but the proportion of death in each group was small and we could not find any meaningful results.

4\. In the discussion part, please correct \"1,845 bone metastasis patients\" into \"1,849\".

Thank you for your comment. I corrected it.

Reviewer \#3:

The definition of SRE (Skeletal-related events) about radiation is slightly different for each paper. (severe bone pain requiring radiation vs. just radiation to bone)

In some cases, radiation therapy is administered for asymptomatic bone metastases in patients to reduce the risk of skeletal-related events. Therefore, it must be noted and the authors should concern and describe about this.

Thank you for your comment.

We added your comment for the weaknesses of the discussion. Two reasons for radiation cannot be distinguished from claims data.

"In the definition of radiation therapy, we could not distinguish the reason for radiation therapy because we used the claim data. The radiation therapy is usually performed when bone pain is present, but in some cases, it is also used for asymptomatic patients to reduce the risk of SRE. "

Reviewer \#4:

1\. In material and methods section. I can't easily understand the following sentences. Please explain. "We excluded paticipants who were aged less than 20 years\~ at least 2 years to assess for bone metastases and SREs" What does washout mean?

Our database is from 2002. In the first year, usually we use wash out period for cancer diagnosis because previous prevalent cases may confound incidence. We revised the sentence;

"We used a 1-year washout period to exclude cancer patients who had been diagnosed in the past."

2\. Please add Kaplan-Meier survival curves for OS, and survival after bone metastasis if possible. (You can add just 2 figures, one for OS including all cancer types, and the other for survival after bone metastasis)

Thank you for your comment.

We added two figures.

Reviewer \#5:

1\. This study focused on 7 major cancer types (stomach, colorectal, liver, lung, breast, prostate, and other genitourinary cancers). The reference about Korea cancer incidence should be added.

We inserted reference about cancer statistics in Korea.

2\. Why did authors use the only C795 for bone metastases? The reason should be documented in discussion.

C795 is ICD-10 code for bone metastasis. We added an explanation for the code.

3\. Authors defined pathologic fracture, spinal cord compression, bone radiation, and bone surgery as SREs. Why did authors exclude hypercalcemia from SREs?

Thank you for your comment. Unfortunately, in health insurance claim data, it was impossible to retrieve the value of hypercalcemia. In terms of definition of SRE, some papers included hypercalcemia, but some papers did not include hypercalcemia depending on authors.

And what was the procedure cord for bone surgery?

We added procedure codes for bone surgery in study population.

How did authors handle overlapping data from the different cords?

We count 1st SRE event as index event for individual patient.

I don't understand this sentence "In addition, patients diagnosed in 2002 were excluded for washout and were followed up for at least 2 years to assess for bone metastases and SREs".

Our database is from 2002. In the first year, usually we use wash out period for cancer diagnosis because previous prevalent cases may confound incidence. We revised the sentence;

"We used a 1-year washout period to exclude cancer patients who had been diagnosed in the past."

4\. In result, authors commented that bone mets increased with age and there was no difference in region or household. Statistical p value should be added. If authors did not use statistical analysis, the content should be corrected.

Thank you for your critical comments. As your advice, we added statistical p value in table 2 and corrected my manuscript.

"Bone metastases showed an increasing trend in rural areas compared to that in urban areas. Household income had no impact on the occurrence of bone metastasis."

5\. Discussion is ambiguous and extensive. This cloud the issue. Please clarify authors' suggestion and present specified contents.

Thank you. We revised the discussion part.

6\. The manuscript is not easy to read and the English used really should be checked for grammar and spelling.

We requested English proofreading once again and submit it with completion. Thank you.

###### 

Submitted filename: Response to Reviewers.docx

###### 

Click here for additional data file.
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Dear Dr. Hong,

We're pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you'll receive an e-mail detailing the required amendments. When these have been addressed, you'll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at <http://www.editorialmanager.com/pone/>, click the \'Update My Information\' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they'll be preparing press materials, please inform our press team as soon as possible \-- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.

Kind regards,

Jason Chia-Hsun Hsieh, M.D. Ph.D

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

All the questions were answered adequately.

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: All comments have been addressed

Reviewer \#2: All comments have been addressed

Reviewer \#3: All comments have been addressed

Reviewer \#4: All comments have been addressed

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: Yes

Reviewer \#3: Yes

Reviewer \#4: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: N/A

Reviewer \#2: Yes

Reviewer \#3: Yes

Reviewer \#4: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

Reviewer \#3: Yes

Reviewer \#4: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

Reviewer \#3: Yes

Reviewer \#4: Yes

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: The authors have addressed questions posed by reviewers. I recommend acceptance of this revised version

Much improvement in English grammar

Reviewer \#2: The authors have addressed all the issues raised sufficiently. This manuscript may be now acceptable for publication.

Reviewer \#3: I reviewed the revised manuscript submitted by the authors.

The authors responded appropriately to what I pointed out.

Reviewer \#4: (No Response)

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

Reviewer \#3: No

Reviewer \#4: No
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Bone metastasis and skeletal-related events in patients with solid cancer: a Korean nationwide health insurance database study

Dear Dr. Hong:

I\'m pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they\'ll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <onepress@plos.org>.

If we can help with anything else, please email us at <plosone@plos.org>.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Jason Chia-Hsun Hsieh

Academic Editor

PLOS ONE
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